Research

LIke ThisLIke ThisLIke This

Rachael Grace, MD

Rachael Grace MD
Research Center:
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Department:
Medicine Research
Division
Hematology/Oncology Research
Hospital Title:
Assistant Physician in Pediatric Medicine
Academic Title:
Assistant Professor of Pediatrics, Harvard Medical School
Contact:
617-355-8246
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Publications

Publications powered by Harvard Catalyst Profiles
  1. Lacy JN, Ulirsch JC, Grace RF, Towne MC, Hale J, Mohandas N, Lux SE, Agrawal PB, Sankaran VG. Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia. Cold Spring Harb Mol Case Stud. 2016 Jul; 2(4):a000885.
  2. Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 Aug; 63(8):1407-13.
  3. Stredny CM, Frosch O, Singhi S, Furutani E, Durbin AD, Grace RF, Ullrich NJ. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 Sep; 62:66-70.
  4. Grace RF, Zanella A, Neufeld EJ, Morton DH, Eber S, Yaish H, Glader B. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015 Sep; 90(9):825-30.
  5. Neunert CE, Grace RF. Thrombopoietin-receptor agonists in children with immune thrombocytopenia. Lancet. 2015 Oct 24; 386(10004):1606-9.
  6. Frelinger AL, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9.
  7. Archer NM, Samnaliev M, Grace R, Brugnara C. The utility of the DDAVP challenge test in children with low von Willebrand factor. Br J Haematol. 2015 Sep; 170(6):884-6.
  8. Schoettler M, Elisofon SA, Kim HB, Blume ED, Rodig N, Boyer D, Neufeld EJ, Grace RF. Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatr Blood Cancer. 2015 Feb; 62(2):214-218.
  9. Morrison JF, Neufeld EJ, Grace RF. The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. Eur J Haematol. 2014 Aug; 93(2):161-4.
  10. Grace RF. Standardized clinical assessment and management plans (SCAMPs): perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia. Semin Hematol. 2013 Jan; 50 Suppl 1:S31-8.
  11. Show all
  12. Neufeld EJ, Galanello R, Viprakasit V, Aydinok Y, Piga A, Harmatz P, Forni GL, Shah FT, Grace RF, Porter JB, Wood JC, Peppe J, Jones A, Rienhoff HY. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood. 2012 Apr 5; 119(14):3263-8.
  13. Long M, Kalish LA, Neufeld EJ, Grace RF. Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects. Am J Hematol. 2012 Mar; 87(3):315-7.
  14. Grace RF, Bennett CM, Ritchey AK, Jeng M, Thornburg CD, Lambert MP, Neier M, Recht M, Kumar M, Blanchette V, Klaassen RJ, Buchanan GR, Kurth MH, Nugent DJ, Thompson AA, Stine K, Kalish LA, Neufeld EJ. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer. 2012 Feb; 58(2):221-5.
  15. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, Deangelo DJ, Silverman LB. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9.
  16. Grace RF, Mednick RE, Neufeld EJ. Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatr Blood Cancer. 2009 Jul; 52(7):865-7.
  17. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia. 2006 May; 12(3):218-22.
  18. Fox RA, Sigman M, Boekelheide K. Transmembrane versus soluble stem cell factor expression in human testis. J Androl. 2000 Jul-Aug; 21(4):579-85.
  19. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997 Dec; 99(4):939-44.
  20. Royer WE, Fox RA, Smith FR, Zhu D, Braswell EH. Ligand linked assembly of Scapharca dimeric hemoglobin. J Biol Chem. 1997 Feb 28; 272(9):5689-94.
  21. Grace RF, Long M, Kalish LA, Neufeld EJ. Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer. 2012 Feb; 58(2):216-20.
  22. Bergmann AK, Grace RF, Neufeld EJ. Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol. 2010 Jul; 89 Suppl 1:S95-103.
  23. Grace RF, Su H, Sena L, Poussaint TY, Heeney MM, Gutierrez A. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. Am J Hematol. 2010 Feb; 85(2):135-7.
  24. Lee EY, Kritsaneepaiboon S, Arellano CM, Grace RF, Zurakowski D, Boiselle PM. Unsuspected pulmonary emboli in pediatric oncology patients: detection with MDCT. AJR Am J Roentgenol. 2010 May; 194(5):1216-22.
  25. Schoettler ML, Graham D, Tao W, Stack M, Shu E, Kerr L, Neufeld EJ, Grace RF. Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP(®) ). Pediatr Blood Cancer. 2016 Oct 26.
LIke ThisLIke ThisLIke This

RELATED RESEARCH CENTER

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top research centers in the world for pediatric cancers and blood diseases. It brings together laboratory scientists and clinical researchers from Dana-Farber Cancer Institute and Boston Children’s Hospital in a single program. We investigate pediatric cancers and non-malignant blood disorders from every angle—from examining cells under the microscope to tracking the effectiveness of current drug regimens using the most advanced molecular methods—so that we can create better treatments for children seen here and around the world.

Learn more
Close